Objective: Potential clinical utility of galanin or peptidic analogs has been hindered by poor metabolic stability, lack of brain penetration, and hyperglycemia due to galanin receptor subtype 1 (GalR1) activation. NAX 810-2, a galanin receptor subtype 2 (GalR2)-preferring galanin analog, possesses 15-fold greater affinity for GalR2 over GalR1 and protects against seizures in the mouse 6 Hz, corneal kindling, and Frings audiogenic seizure models. The purpose of these studies was to further evaluate the preclinical efficacy and pharmacokinetics of NAX 810-2 in mice. Methods: NAX 810-2 was administered by intravenous (i.v.; tail vein, bolus) injection to fully kindled (corneal kindling assay) or naive CF-1 mice (6 Hz assay and pharmacokinetic studies). Plasma NAX 810-2 levels were determined from trunk blood samples. NAX 810-2 was also added to human plasma at various concentrations for determination of plasma protein binding. Results: In the mouse corneal kindling model, NAX 810-2 dose-dependently blocked seizures following intravenous administration (median effective dose [ED 50 ], 0.5 mg/ kg). In the mouse 6 Hz (32 mA) seizure model, it was demonstrated that NAX 810-2 dose-dependently blocked seizures following bolus administration (0.375-1.5 mg/kg, i.v.; ED 50 , 0.7 mg/kg), with a time-to-peak effect of 0.5 h posttreatment. Motor impairment was observed at 1.5 mg/kg, i.v., whereas one-half of this dose, 0.75 mg/kg, i.v., was maximally effective in the 6 Hz test. Plasma levels of NAX 810-2 show linear pharmacokinetics following intravenous administration and a half-life of 1.2 h. Functional agonist activity studies demonstrate that NAX 810-2 effectively activates GalR2 at therapeutic concentrations. Significance: These studies further suggest the potential utility of NAX 810-2 as a novel therapy for epilepsy.
Galanin is one of several neuropeptides with demonstrated anticonvulsant activity. 1, 2 Both galanin receptor subtype 1 (GalR1) and subtype 2 (GalR2) have been shown to play a role in seizures. 3, 4 However, the development of galanin as an anticonvulsant has been hindered by poor metabolic stability, a lack of effective penetration across the blood-brain barrier, and GalR1-mediated insulin inhibition in several species. 5 Galanin and its receptors are localized in several regions of the central nervous system (CNS), including the hippocampus, where a high density of galaninimmunoreactive fibers are found in the dentate granule cell layer. 6 Galanin has also been shown to inhibit glutamate release via presynaptic action, 7, 8 and galanin knockout mice produce a larger release of glutamate in response to depolarization. 9 Anticonvulsant effects of galanin have been demonstrated in several animal models. Central administration of galanin decreases the severity of evoked seizures in a rat kindling model. 10 Furthermore, both GalR1 and GalR2 agonists have been used in a performant path stimulationinduced model of status epilepticus (SE) to demonstrate that GalR1 and GalR2 play differential roles in initiation and maintenance of SE, respectively. 11 Similarly, infusion of with GalR2 complementary peptide nucleic antisense oligonucleotides increased the time spent in seizures in a hippocampal stimulation seizure model. 3 We previously described high-affinity and systemically active galanin analogs, with preference for either GalR1 or GalR2, that were potently active in the 6 Hz model of psychomotor seizures. 12 We further characterized a lead GalR1-preferring analog, NAX 505-5, in the 6 Hz (including 22, 32, and 44 mA stimulus intensities), corneal kindling, Frings audiogenic seizure, maximal electroshock, and pentylenetetrazol seizure models. 13 We also demonstrated that galanin analogs could be engineered to discriminate between GalR1 and GalR2 and retain anticonvulsant efficacy. 14 The lead GalR2-preferring analog, NAX 810-2, was designed and previously shown to prevent seizures in a variety of animal models. 15, 16 Initially, NAX 810-2 was evaluated for antiseizure efficacy following intraperitoneal (i.p.) administration and demonstrated efficacy in the 6 Hz model (32, 44 mA), audiogenic seizures, and corneal kindling. 15 In addition, this compound was further evaluated in the 6 Hz and corneal kindling models following intravenous administration. 16 These studies extend previous antiseizure efficacy observations by the following: (1) using an optimized formulation of NAX 810-2 for evaluation in mouse seizure models (e.g., corneal kindling and 6 Hz seizure models) following intravenous administration; and (2) comparing intravenous NAX 810-2 efficacy in the 6 Hz model with corresponding plasma levels in a pharmacokineticpharmacodynamic interaction study. Additional analysis was conducted to determine several pharmacokinetic parameters and evaluate whether the compound demonstrates linear pharmacokinetics.
Methods

Animals
Male albino CF-1 mice (18-38 g; Charles River, Kingston, NY, U.S.A.) were used as experimental animals. Mice evaluated in the 6 Hz model were 22-32 g, whereas mice evaluated in the corneal kindling model were generally 30-38 g at the time of testing. All animals were allowed free access to food and water, except during testing procedures. Experimental procedures were approved by the Institutional Animal Care and Use Committee at the University of Utah and were carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted by the National Institutes of Health.
NAX 810-2 preparation and formulation NAX 810-2 (mol. wt. 2,124 g/mol) was synthesized by PolyPeptide Laboratories (San Diego, CA, U.S.A.), and delivered as a lyophilized material (acetate salt, purity > 95%). The compound was supplied as a diastereoisomeric mixture (40/60) arising from a racemic mixture of N-methyl-tryptophan, the N-terminal amino acid of the peptide (structure described previously 15 ). The compound was dissolved in a vehicle (VEH) solvent consisting of 2% hydroxyl-propyl-beta cyclodextrin (HPbCD; Sigma, St. Louis, MO, U.S.A.) in acetate buffer (0.1 M acetic acid, 0.1 M sodium acetate; pH 4.5; 0.1 M acetic acid prepared from glacial acetic acid stock, Sigma; sodium acetate, Sigma).
Mouse 6 Hz psychomotor seizure model
Seizures were induced via corneal stimulation (6 Hz, 0.2 ms rectangular pulse, 3 s duration; 32 mA stimulus intensity) using a Grass S48 stimulator. 17 Prior to stimulation, 1-2 drops of tetracaine were applied to each eye. The limbic seizures that arise from corneal stimulation in this assay are characterized by automatistic behaviors including stun, forelimb clonus, twitching of the vibrissae, and Straub tail. Animals that did not demonstrate these behaviors following corneal stimulation (up to 1-min observation poststimulation) were considered "protected."
Mouse corneal kindling model
The corneal kindled mouse displays phenotypic secondarily generalized seizures (Racine scale 18 ) and a pharmacologic profile consistent with other models of kindling (e.g., amygdala-and hippocampus-kindled rats). Mice received twice daily subthreshold corneal stimulations (60 Hz, 3 mA, 3 s; 5 days/week,~3 weeks 19 ) until reaching the criterion of five consecutive secondarily generalized seizures (Racine scale 5), at which point they were Key Points • Development of the anticonvulsant neuropeptide galanin as a novel therapeutic has been hindered because of poor metabolic stability, lack of blood-brain barrier penetration, and activation of the insulin-inhibiting GalR1
• NAX 810-2 is a GalR2-preferring peptide analog with activity in mouse preclinical seizure models following systemic administration including the 6 Hz and corneal kindling models considered "fully kindled." One day prior to treatment, the fully kindled state was verified (presence of a stage 5 seizure) by a single stimulation. NAX 810-2 was administered by intravenous bolus (0.1 ml per 10 g) into a lateral tail vein of each kindled mouse. Animals were considered "protected" if they displayed a Racine seizure score of 0-3.
Rotarod test for motor impairment
Testing in the rotarod assay was conducted immediately prior to corneal stimulation in 6 Hz and cornealkindling studies. When mice are placed on a 1-inch knurled rod rotating at a speed of 6 rpm, the animals can maintain equilibrium for long time periods. Motor impairment was assessed by determining whether mice remained on the rotarod during a 1-min observation period, that is, three falls during a 1-min period was considered a rotarod failure.
Sample collection for determination of plasma NAX 810-2 levels
Following testing in the mouse 6 Hz model, trunk blood was collected (time points: 0.08, 0.25, 0.5, 0.75, 1, 2, 3, 4, and 6 h) into potassium ethylenediaminetetraacetic acid (K2EDTA)-coated microcentrifuge tubes (500 ml capacity; Beckton Dickinson Company, Franklin Lakes, NJ, U.S.A.). Following centrifugation (10,000 g) at 4°C for 10 min, plasma samples were transferred to uncoated microcentrifuge tube and stored (À80°C) until processing for NAX 810-2 concentrations.
Plasma protein binding
NAX 810-2 was added to human plasma at various concentrations (0.5, 5, and 50 lM) and in a centrifuge tube and subjected to centrifugation for 16-24 h at 200,000 9 g max . The concentration of NAX 810-2 in the supernatant was determined by a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method using LC-20A Shimadzu high-performance liquid chromatography (HPLC) and API4000 AB SCIEX mass spectrometer. For HPLC separations, a reverse-phase C18 column (3 mm, 2.1 9 50 mm, Shiseido) and a linear gradient acetonitrile in 0.2% formic acid were used. A positive control, warfarin (10 lM), was included.
GalR1 and GalR2 functional activity
NAX 810-2 was evaluated using EMD Millipore's GPCRProfiler Assay. NAX 810-2 was dissolved in dimethyl sulfoxide and prepared in various assay buffer concentrations (up to 3 times higher than highest assay concentration: 2.0/0.5/0.1 lM) using a modified Hanks balanced salt solution (HBSS) with an addition of 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 2.5 mM probenecid, pH 7.4. Reference controls for GalR1 and GalR2 were galanin (amino acids 1-30) (GalR1, E max 0.0375 lM; GalR2, E max 0.125 lM).
Each concentration was evaluated in duplicate. The agonist assay was conducted on a FLIPR TETRA instrument, wherein NAX 810-2, vehicle controls, and galanin (amino acids 1-30) were added to the assay plate after a baseline fluorescence/luminescence was determined. Maximum fluorescence/luminescence values were corrected for baseline values, and a percentage of activation was determined: [(maximum activity, relative luminescence units)À(baseline average activity)]/[positive averageÀbaseline average].
LC-MS method for determination of plasma NAX 810-2 levels
Plasma levels of NAX 810-2 were determined using liquid-liquid extraction followed by LC/MS. Plasma samples (25 ll) were added to 96-well plates followed by addition of an internal standard solution (200 ll) containing NAX 810-1 (internal standard) in acetonitrile with 1% formic acid. The final solutions were mixed and subjected to centrifugation (1000 9 g) for 5 min, after which 100 ll of the supernatant was removed and added to a solution of water (100 ll) containing 1% formic acid. NAX 810-2 levels were evaluated by an LC method using an HPLC system (Shimadzu SCL-10A), reverse-phase column (Varian Metasil AQ C18 50 9 2.1 mm), and a linear gradient of mobile phases consisting of water and acetonitrile with 1% formic acid. Following liquid chromatography, samples were added to an API-5500 mass spectrometer using electrospray ionization (5,000 V, 700°C). NAX 810-2 levels were evaluated based on a mass transition of 709.0?693.8 m/z.
Median effective dose (ED 50 ) determination and statistical analysis
Median effective dose (ED 50 ) and 95% confidence interval (CI) values in the corneal kindling and 6 Hz assays were calculated using Probit analysis. Data are presented as means AE standard error. Individual means were compared using a t-test, and multiple means were compared using a one-way analysis of variance (ANOVA) followed by a Dunnett post hoc evaluation for comparison to VEH.
Pharmacokinetic parameter analysis
A noncompartmental analysis was employed to obtain pharmacokinetic parameters. The half-life (t 1/2 ) was calculated as 0.693/k z , where k z is the terminal slope of the drug concentration versus time curve. Area under the curve (AUC), corresponding to the area under the drug concentration versus time curve, was calculated using the trapezoidal rule and extrapolated to infinity. Clearance (CL) was calculated from the quotient dose/ AUC. The apparent volume of distribution (V d /F) or estimated volume of distribution was calculated as CL/F divided by the linear terminal slope, where F (bioavailability) is 1 following intravenous administration.
Results
NAX 810-2: mouse intravenous efficacy in the corneal kindling model
A time-to-peak effect in corneal kindling for NAX 810-2 following intravenous administration was previously determined to be 1 h in a time course study (data not shown). Using this time point, several doses of NAX 810-2 (dose range 0.2-3.0 mg/kg) were administered to fully kindled mice. NAX 810-2 showed dose-dependent activity in the corneal kindling assay, with an ED 50 (95% CI) of 0.5 mg/kg (0.1-0.9 mg/kg) (see Table 1 ).
NAX 810-2: mouse intravenous efficacy and in the 6 Hz (32 mA) model NAX 810-2 was administered to separate groups of naive mice prior to testing (0.08-6 h posttreatment) in the 6 Hz (32 mA) assay (see Table 2 ). Immediately prior to 6 Hz testing, mice were evaluated for motor impairment using a rotarod (see Table 2 ). NAX 810-2 was effective in blocking seizures in a dose-dependent manner at several time points (0.08-2 h), with peak activity observed 0.25-0.75 h following treatment. Using activity observed 0.5 h following treatment, the calculated ED 50 (95% CI) for NAX 810-2 in this assay was 0. Pharmacokinetic-pharmacodynamic interaction study of NAX 810-2 following intravenous administration in CF-1 mice Figure 1 shows plasma levels of NAX 810-2 following intravenous bolus administration compared with 6 Hz efficacy (compare with Table 2 ). Plasma concentrations were greatest at the initial time point following treatment (0.08 h postdose); 6 Hz efficacy was maximal at 0.08 h (0.375 mg/kg; 25% protection), 0.75 h (0.5625 mg/kg, 50% protection; 0.75 mg/kg, 100% protection), and 0.75-1 h (1.5 mg/kg) (see Fig. 1A) . AUC values derived from the NAX 810-2 concentration versus time curve are shown in Figure 1B and show a linear increase with increasing doses.
Pharmacokinetic parameters derived from analysis of the NAX 810-2 plasma-concentration versus time relationship and are shown in Table 3 To further evaluate the relationship between behavioral observations (6 Hz and rotarod assays) and plasma NAX 810-2 levels, plasma levels were compared at the times of peak 6 Hz protection (0.5 and 0.75 h; see Fig. S1A ) and peak motor impairment in the rotarod assay (0.25 and 0.75 h; see Fig. S1B ). Plasma NAX 810-2 increase in a dose-dependent manner to efficacy and motor impariment.
Plasma protein binding
NAX 810-2 was evaluated at several concentrations (0.5, 5, 50 lM) for plasma protein binding in human plasma in comparison to warfarin (10 lM). At all concentrations tested, NAX 810-2 was observed to be highly protein bound: 0.5 lM, 99.5 AE 0.1% bound; 5 lM, 99.7 AE 0.1% bound; and 50 lM, 100.0 AE 0.0% bound (see Table S1 ).
GalR functional activity
Activity of NAX 810-2 in functional agonist activity assays for GalR1 and GalR2 are shown in Table 4 . The compound was evaluated at concentrations of 0.1, 0.5, and 2.0 lM at each receptor. NAX 810-2 shows preferential activity for GalR2 over GalR1 at concentrations of 0.1 and 0.5 lM, respectively, whereas agonist activity was similar at both receptors at the highest concentration tested (2.0 lM). 
Discussion
This work confirms and expands our initial findings that GalR2-preferring analogs have favorable preclinical properties as antiseizure drug leads. The preclinical pharmacology of NAX 810-2 following intraperitoneal and intravenous administration has been described previously.
15,16 NAX 810-2 dose-dependently blocks seizures in the mouse 6 Hz model at both 32 and 44 mA stimulus intensities and in the mouse corneal kindling model following intraperitoneal administration and is effective following intravenous administration in the mouse 6 Hz (32 mA) and corneal kindling models. Following these initial studies, an optimized formulation of NAX 810-2 was prepared to improve solubility for intravenous administration studies. NAX 810-2 dose-dependently reduced seizures in the 6 Hz (32 mA) and corneal kindling models. Doses up to 0.75 mg/kg, i.v., were generally well tolerated, producing minimal motor impairment in the rotarod assay. The experiments reported in this mansucript therefore extend previous studies by demonstrating dose-dependent efficacy in mouse corneal kindling and mouse 6 Hz seizure models using an optimized formulation of NAX 810-2. Furthermore, using pharmacokinetic-pharmacodynamic analysis, we observed that the compound has linear pharmacokinetics, and peak plasma concentrations coincide with peak antiseizure activity.
NAX 810-2 demonstrates linear pharmacokinetics, with dose-dependent increases in AUC and plasma levels. Several of the currently available antiseizure drugs exhibit pharmacokinetic properties that create challenges for use in clinical settings. For example, phenytoin, carbamazepine, and valproic acid can exhibit nonlinear pharmacokinetics, wherein increases in dose do not result in proportional increases in plasma concentrations, thereby furthering the risk of untoward effects. 20 Therefore, demonstration of linear pharmacokinetics at therapeutically relevant concentrations for NAX 810-2 is a distinct advantage for this novel antiseizure drug. However, it is noteworthy that NAX 810-2 also demonstrated a high degree of plasma protein binding. At a concentration of 0.5 lM, which corresponds to concentrations of approximately 1,000 ng/ml (within the range of plasma levels associated with antiseizure efficacy in the 6 Hz model), NAX 810-2 was 99.5% protein bound. This suggests that small changes in the ratio of bound/unbound NAX 810-2 may have dramatic effects on efficacy and toxicity. Further development of this compound as a novel therapeutic will therefore require careful consideration of coadministered drugs.
NAX 810-2 is effective in the corneal kindling model but not the maximal electroshock seizure model, 16 and therefore demonstrates a preclinical seizure profile similar to that of levetiracetam. 21, 22 Despite this similar profile, the mechanism of action of NAX 810-2 is distinct from that of levetriacetam. By binding to SV2A, 23 levetiracetam has a unique mode of action via presynaptic inhibition of neurotransmitter release. 24 Although the mechanism of action of GalR2 in epileptic neural circuits has not been fully described, galanin stores can be mobilized during acute seizure insults 25 and GalR2s are highly expressed in the granule cell layer of the dentate gyrus. 26 These and other observations have led to the hypothesis that galanin acts as an endogenous anticonvulsant. Furthermore, the anticonvulsant actions of galanin analogs may occur via both presynaptic and postsynaptic modes of action. 27, 28 In addition, future studies could include coadministration of NAX 810-2 with levetiracetam to determine whether there are additive or synergistic effects arising from combined administration of compounds with presynaptic mechanisms of action.
Functional agonist studies for GalR1 and GalR2 demonstrated that NAX 810-2 is GalR2 preferring at concentrations of 0.1 and 0.5 lM, but were equally active for GalR1 and GalR2 at 2.0 lM. In addition, NAX 810-2 0.5 lM corresponds to 1,062 ng/ml, which is similar to the plasma concentration observed following a dose of 0.75 mg/kg, which was maximally effective in the 6 Hz assay. Therefore, these data suggest that NAX 810-2 is GalR2 preferring at therapeutically relevant doses and this GalR2 preference diminishes at supratherapeutic doses.
Previous efforts to develop compounds that act on galanin receptors have included the small molecules galmic 6, 29, 30 and galnon, 6, 31 galanin peptide fragments, 6 and galanin allosteric modulators. 32 Galmic and galnon were hindered as novel therapeutics due to low affinity (i.e., compared to peptide ligands) and a lack of selectivity for GalR1 and/or GalR2. 6, 33 Galanin and galanin peptide fragments have proven effective against seizures when administered centrally, 6, 25 although systemic administration has been challenged by metabolic stability and lack of blood-brain barrier penetration. By contrast, NAX 810-2 is systemically active in acute seizure models, following both intravenous and intraperitoneal administration, and this efficacy was observed at doses that did not produce motor impairment. Efficacy in the mouse 6 Hz and corneal kindling seizure models suggests that this compound crosses the blood-brain barrier and affects neuronal excitability. Previously we have observed that the galanin fragment Gal(1-16) and synthesized galanin analogs are effective in the mouse 6 Hz model following intracerebroventricular injection 12,34 even when a Percent activation normalized to maximal activity for positive control samples, galanin .
these analogs are restricted to the periphery, 34 suggesting that central activation of galanin receptors can block seizures. Future studies will include determination of brain NAX 810-2 levels for confirmation of brain penetration and comparison to antiseizure activity.
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